List of Tables
Table 1. Global Secondary Progressive Multiple Sclerosis Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Secondary Progressive Multiple Sclerosis Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Secondary Progressive Multiple Sclerosis Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
Table 5. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Secondary Progressive Multiple Sclerosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Secondary Progressive Multiple Sclerosis Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Secondary Progressive Multiple Sclerosis Drug, Product Type & Application
Table 12. Global Key Manufacturers of Secondary Progressive Multiple Sclerosis Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Secondary Progressive Multiple Sclerosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025) & (K Pcs)
Table 18. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2020-2025)
Table 19. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2026-2031) & (K Pcs)
Table 20. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2026-2031)
Table 21. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 27. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2026-2031) & (K Pcs)
Table 28. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 32. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2026-2031) & (K Pcs)
Table 33. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025) & (K Pcs)
Table 37. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2026-2031) & (K Pcs)
Table 38. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 42. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2026-2031) & (K Pcs)
Table 43. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2026-2031) & (K Pcs)
Table 48. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2020-2025)
Table 51. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2026-2031)
Table 52. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Table 53. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2026-2031)
Table 54. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Type (2020-2025)
Table 59. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Type (2026-2031)
Table 60. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Application (2020-2025)
Table 61. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Application (2026-2031)
Table 62. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Table 63. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2026-2031)
Table 64. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Application (2020-2025)
Table 69. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Application (2026-2031)
Table 70. AB Science SA Company Information
Table 71. AB Science SA Description and Business Overview
Table 72. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 73. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product
Table 74. AB Science SA Recent Developments/Updates
Table 75. Actelion Ltd Company Information
Table 76. Actelion Ltd Description and Business Overview
Table 77. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 79. Actelion Ltd Recent Developments/Updates
Table 80. Biogen, Inc. Company Information
Table 81. Biogen, Inc. Description and Business Overview
Table 82. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 84. Biogen, Inc. Recent Developments/Updates
Table 85. F. Hoffmann-La Roche Ltd. Company Information
Table 86. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 87. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 89. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 90. Genzyme Corporation Company Information
Table 91. Genzyme Corporation Description and Business Overview
Table 92. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product
Table 94. Genzyme Corporation Recent Developments/Updates
Table 95. Glialogix, Inc. Company Information
Table 96. Glialogix, Inc. Description and Business Overview
Table 97. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 99. Glialogix, Inc. Recent Developments/Updates
Table 100. Immune Response BioPharma, Inc. Company Information
Table 101. Immune Response BioPharma, Inc. Description and Business Overview
Table 102. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 104. Immune Response BioPharma, Inc. Recent Developments/Updates
Table 105. Innate Immunotherapeutics Ltd Company Information
Table 106. Innate Immunotherapeutics Ltd Description and Business Overview
Table 107. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 109. Innate Immunotherapeutics Ltd Recent Developments/Updates
Table 110. Kyorin Pharmaceutical Co., Ltd. Company Information
Table 111. Kyorin Pharmaceutical Co., Ltd. Description and Business Overview
Table 112. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 114. Kyorin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 115. Mallinckrodt Plc Company Information
Table 116. Mallinckrodt Plc Description and Business Overview
Table 117. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product
Table 119. Mallinckrodt Plc Recent Developments/Updates
Table 120. MedDay SA Company Information
Table 121. MedDay SA Description and Business Overview
Table 122. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 123. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product
Table 124. MedDay SA Recent Developments/Updates
Table 125. MedImmune, LLC Company Information
Table 126. MedImmune, LLC Description and Business Overview
Table 127. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 128. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product
Table 129. MedImmune, LLC Recent Developments/Updates
Table 130. Merck KGaA Company Information
Table 131. Merck KGaA Description and Business Overview
Table 132. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 133. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product
Table 134. Merck KGaA Recent Developments/Updates
Table 135. Meta-IQ ApS Company Information
Table 136. Meta-IQ ApS Description and Business Overview
Table 137. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 138. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product
Table 139. Meta-IQ ApS Recent Developments/Updates
Table 140. Novartis AG Company Information
Table 141. Novartis AG Description and Business Overview
Table 142. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 143. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product
Table 144. Novartis AG Recent Developments/Updates
Table 145. Opexa Therapeutics, Inc. Company Information
Table 146. Opexa Therapeutics, Inc. Description and Business Overview
Table 147. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 148. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 149. Opexa Therapeutics, Inc. Recent Developments/Updates
Table 150. Xenetic Biosciences (UK) Limited Company Information
Table 151. Xenetic Biosciences (UK) Limited Description and Business Overview
Table 152. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 153. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product
Table 154. Xenetic Biosciences (UK) Limited Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 158. Secondary Progressive Multiple Sclerosis Drug Customers List
Table 159. Secondary Progressive Multiple Sclerosis Drug Market Trends
Table 160. Secondary Progressive Multiple Sclerosis Drug Market Drivers
Table 161. Secondary Progressive Multiple Sclerosis Drug Market Challenges
Table 162. Secondary Progressive Multiple Sclerosis Drug Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. Authors List of This Report
List of Figures
Figure 1. Product Picture of Secondary Progressive Multiple Sclerosis Drug
Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Type: 2024 & 2031
Figure 4. Inebilizumab Product Picture
Figure 5. GLX-1112 Product Picture
Figure 6. DC-TAB Product Picture
Figure 7. Etomoxir Product Picture
Figure 8. IB-MS Product Picture
Figure 9. Others Product Picture
Figure 10. Global Secondary Progressive Multiple Sclerosis Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Application: 2024 & 2031
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Market Size (2020-2031) & (US$ Million)
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Sales (2020-2031) & (K Pcs)
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) & (2020-2031)
Figure 19. Secondary Progressive Multiple Sclerosis Drug Report Years Considered
Figure 20. Secondary Progressive Multiple Sclerosis Drug Sales Share by Manufacturers in 2024
Figure 21. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest Secondary Progressive Multiple Sclerosis Drug Players: Market Share by Revenue in Secondary Progressive Multiple Sclerosis Drug in 2024
Figure 23. Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2031)
Figure 26. North America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2031)
Figure 27. U.S. Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2031)
Figure 30. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2031)
Figure 31. Germany Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2020-2031)
Figure 38. China Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Taiwan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Indonesia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Thailand Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Malaysia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Philippines Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2031)
Figure 49. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2031)
Figure 50. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Argentina Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2031)
Figure 54. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2031)
Figure 55. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. UAE Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Global Sales Market Share of Secondary Progressive Multiple Sclerosis Drug by Type (2020-2031)
Figure 59. Global Revenue Market Share of Secondary Progressive Multiple Sclerosis Drug by Type (2020-2031)
Figure 60. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Type (2020-2031)
Figure 61. Global Sales Market Share of Secondary Progressive Multiple Sclerosis Drug by Application (2020-2031)
Figure 62. Global Revenue Market Share of Secondary Progressive Multiple Sclerosis Drug by Application (2020-2031)
Figure 63. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Application (2020-2031)
Figure 64. Secondary Progressive Multiple Sclerosis Drug Value Chain
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
